JGC
JAZZ icon

J. Goldman & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

J. Goldman & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,969
Closed -$2.11M – 546
2024
Q3 		$2.11M Sell
18,969
-57,916
-75% -$6.35M 0.06% 226
2024
Q2 		$8.21M Buy
+76,885
New +$8.45M 0.23% 126
2024
Q1 		– Sell
-36,497
Closed -$4.47M – 459
2023
Q4 		$4.49M Buy
+36,497
New +$4.55M 0.18% 136
2021
Q1 		– Sell
-12,586
Closed -$2.08M – 483
2020
Q4 		$2.08M Buy
12,586
+5,101
+68% +$760K 0.11% 190
2020
Q3 		$1.07M Sell
7,485
-12,940
-63% -$1.6M 0.07% 211
2020
Q2 		$2.25M Buy
+20,425
New +$2.26M 0.14% 152
2017
Q4 		– Sell
-7,500
Closed -$1.1M – 388
2017
Q3 		$1.1M Sell
7,500
-7,800
-51% -$1.18M 0.06% 234
2017
Q2 		$2.38M Sell
15,300
-50,400
-77% -$7.71M 0.13% 167
2017
Q1 		$9.54M Buy
65,700
+26,200
+66% +$3.41M 0.47% 62
2016
Q4 		$4.31M Sell
39,500
-32,300
-45% -$3.6M 0.29% 110
2016
Q3 		$8.72M Buy
71,800
+7,800
+12% +$1.05M 0.49% 56
2016
Q2 		$9.04M Buy
+64,000
New +$9.43M 0.47% 46

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

J. Goldman & Co's JAZZ Position: Q4 2024 in Review

J. Goldman & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 18,969 shares — an estimated $2.11M sold.

J. Goldman & Co first reported a position in JAZZ in Q2 2016 and held it in 12 quarters. The position peaked at $9.54M in Q1 2017. 509 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • J. Goldman & Co reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • J. Goldman & Co sold 18,969 Jazz Pharmaceuticals shares in Q4 2024, an estimated $2.11M.
  • J. Goldman & Co first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 12 quarters.
  • J. Goldman & Co's Jazz Pharmaceuticals position peaked at $9.54M in Q1 2017.
  • 509 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.